Clinical efficacy of decitabine in combination with standard-dose cytarabine, aclarubicin hydrochloride, and granulocyte colony-stimulating factor in the treatment of young patients with newly diagnosed acute myeloid leukemia
| Autor: | Wenrong Huang, Yu Jing, Jun-Hui Mei, Dai-Hong Liu, Yang Xiao, Jian Bo, Qingyu Xu, Longcan Cheng, Mengzhen Wang, Li Yu, Li-Ping Dou, Hong-Hua Li |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Decitabine acute myeloid leukemia Neutropenia OncoTargets and Therapy 03 medical and health sciences Myelogenous 0302 clinical medicine conventional chemotherapy Internal medicine medicine Idarubicin Pharmacology (medical) Original Research business.industry induction therapy Myeloid leukemia Induction chemotherapy medicine.disease Leukemia 030104 developmental biology 030220 oncology & carcinogenesis Cytarabine business decitabine medicine.drug |
| Zdroj: | OncoTargets and therapy |
| ISSN: | 1178-6930 |
| Popis: | Liping Dou,1,2* Qingyu Xu,1* Mengzhen Wang,1* Yang Xiao,1* Longcan Cheng,2 Honghua Li,1 Wenrong Huang,1 Junhui Mei,1 Yu Jing,1 Jian Bo,1,2 Daihong Liu,1 Li Yu11Department of Hematology, Chinese PLA General Hospital, Beijing 100853, People’s Republic of China; 2Department of Hematology, Hainan Branch of Chinese PLA General Hospital, Sanya, Hainan 572013, People’s Republic of China*These authors contributed equally to this work Purpose: The chemotherapeutic regimen DCAG (decitabine with cytarabine, aclarubicin hydrochloride, and granulocyte colony-stimulating factor) is effective for elderly patients with acute myeloid leukemia, but recommendations for young patients remain controversial. This study investigated the tolerance and efficacy of DCAG for patients with newly diagnosed acute myeloid leukemia (aged 14–60 years). The clinical features or molecular markers that may predict response to DCAG were identified.Patients and methods: One-hundred sixty-one consecutive patients with newly diagnosed acute myelogenous leukemia received DCAG or standard (idarubicin plus cytarabine, IA) induction chemotherapy (n=64 and 97, respectively).Results: The rates of complete remission after the first cycle, overall survival (OS), and event-free survival (EFS) were comparable. After the second cycle, the complete remission rate of the DCAG group (54.7%) was significantly lower than that of the reference (78.35%, P=0.005). The following were associated with significantly worse OS, and EFS, in the DCAG group: Eastern Cooperative Oncology Group (ECOG) score ≥3 and no response after the second induction therapy; and FLT3-ITD. The multivariate analysis showed the DCAG group with significantly shorter OS associated with ECOG ≥3 and FLT3-ITD. In the DCAG group, after the first cycle of induction chemotherapy the median recovery times of neutrophils and platelets were 15.8 and 13 days.Conclusion: The DCAG and IA groups were similar with regard to complete remission rate after the first cycle, OS, and EFS. The complete remission rate after the second cycle of the DCAG was significantly lower than that of the IA. Grade 4 neutropenia and thrombocytopenia were a major adverse event associated with DCAG.Keywords: decitabine, acute myeloid leukemia, induction therapy, conventional chemotherapy |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|